Cartana is based at Karolinska Institute in Stockholm and has developed a new technology for researchers to analyse tissue samples in drug development processes. The company is ready to launch at the market for brain research and will launch on the market for cancer research within a few years.
Last updated: 2026-07-07 If you’re used to buying shares on the stock market, it doesn’t have to be a big leap to invest in unlisted companies as well. At Sciety, we frequently receive questions from people who are considering making their first investment in an unlisted company. Practically speaking, how
Neurological disorders have been pinpointed by WHO as one of the greatest threats to public health. As an example, nearly 10 million people develop dementia each year and the number of people living with dementia is expected to triple from 50 million to 152 million by 2050. Today, the annual
Sciety becomes a member in the trade association SwedenBIO that works for a strong life science sector in Sweden. The members include micro companies to big pharma but also companies that provide services in business development, IP, financing and etc. As Sciety works with financing of unlisted companies, in the
The new issue of shares in EMPE Diagnostics was fully subscribed already two weeks before the subscription period expired. EMPE Diagnostics develops a rapid test for diagnosis of tuberculosis. In total, 10 million SEK was invested and the funding will be used for final product validation and market launch.
Last week, the trade associations LIF, Swedish Medtech and SwedenBIO presented an action plan to strengthen the competitiveness of Swedish life science. As Sciety meets many companies that develop the healthcare sector, we find it is very interesting that one of the three topics in the plan is to introduce
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.